Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have received a consensus rating of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $8.08.

Several equities analysts have issued reports on the company. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. HC Wainwright set a $10.00 price objective on Celldex Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “sell” rating in a report on Monday, July 17th. Finally, Aegis reaffirmed a “buy” rating on shares of Celldex Therapeutics in a report on Thursday, June 29th.

Shares of Celldex Therapeutics (NASDAQ CLDX) traded up 0.39% during mid-day trading on Wednesday, reaching $2.57. The company’s stock had a trading volume of 1,477,004 shares. The company’s 50-day moving average is $2.47 and its 200-day moving average is $2.85. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $5.02. The stock’s market capitalization is $329.84 million.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. The firm had revenue of $3.83 million for the quarter, compared to analyst estimates of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. Celldex Therapeutics’s revenue for the quarter was up 175.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.32) earnings per share. Equities analysts predict that Celldex Therapeutics will post ($1.04) EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/16/celldex-therapeutics-inc-cldx-receives-8-08-consensus-target-price-from-analysts.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Celldex Therapeutics by 26.2% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 6,000 shares during the period. BB&T Securities LLC acquired a new stake in shares of Celldex Therapeutics during the second quarter worth about $117,000. Voya Investment Management LLC boosted its stake in shares of Celldex Therapeutics by 17.4% during the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 7,499 shares during the period. Overbrook Management Corp acquired a new stake in shares of Celldex Therapeutics during the second quarter worth about $139,000. Finally, American International Group Inc. boosted its stake in shares of Celldex Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 3,880 shares during the period. Institutional investors and hedge funds own 56.69% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.